The vaccines used for inoculations of the locals in India, including Russia's Sputnik V are considered effective for combating the Delta strain. Dr. N.K. Arora, the Chair of Indian SARS-CoV-2 Genomics Consortium said so in his commentary for Indian news agency ANI.
The official cited the ICMR, the Indian Council of Medical Research, which conducted the respective study that proved the efficiency of these vaccines against this particular strain.
Currently, India uses the vaccine of Indian Institute of Serum (CoviShield), which was created under the license from AstraZeneca, Russia's Sputnik V and a drug developed by Bharat Biotech Covaxin.
"The virus begins to infect the part of population that is most perceptive and vulnerable to this infection. After successfully contaminating considerable part of population, the virus withdraws for some time; and then, it strikes back when the immunity that people developed after natural infection grows weaker", Arora said.